Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Prostate Cancer Treatment and Research, Lung Cancer Treatments and Mutations, and Fibroblast Growth Factor Research.
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial
Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma: A report on behalf of the International Immuno-Oncology Biomarker Working Group.
Development and internal validation of a clinical risk prediction model for pancreatic ductal adenocarcinoma in the UK Biobank
Patritumab deruxtecan in HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer: a phase 2 trial.
Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy.
Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group”
Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians.
Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023.
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.
Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Figure 4 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S10 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S3 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S12 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure 3 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S8 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S13 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure 1 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Table S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S5 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S4 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure 2 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S14 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure S2 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Data from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S6 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S2 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Tables S1-S11 from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer